Climacteric最新文献_第7页

COVID-19 vaccination and postmenopausal bleeding: a retrospective cohort study. COVID-19 疫苗接种与绝经后出血：一项回顾性队列研究。

IF 2.9 4区医学

Climacteric Pub Date : 2024-10-01 Epub Date: 2024-08-12 DOI: 10.1080/13697137.2024.2385360

Lucía Pastor-Goutherot, Ester Miralpeix, Berta Fabregó, Laia Serrano, Adrián Vizoso, Josep-Maria Solé-Sedeño, Gemma Mancebo

{"title":"COVID-19 vaccination and postmenopausal bleeding: a retrospective cohort study.","authors":"Lucía Pastor-Goutherot, Ester Miralpeix, Berta Fabregó, Laia Serrano, Adrián Vizoso, Josep-Maria Solé-Sedeño, Gemma Mancebo","doi":"10.1080/13697137.2024.2385360","DOIUrl":"10.1080/13697137.2024.2385360","url":null,"abstract":"Objective: COVID-19 vaccination has been related to menstrual irregularities; however, the effect on postmenopausal women is unknown. The aim of this study was to analyze the prevalence of postmenopausal bleeding (PMB) after COVID-19 vaccination.Methods: A retrospective study was conducted in the Department of Gynecology in Hospital del Mar. Consecutive postmenopausal women with data available and endometrial biopsy were included between February 2021 and January 2022. Patients were stratified between COVID-19 vaccinated and unvaccinated groups. PMB after 30 days from last vaccine dose was considered unrelated to vaccine. Endometrial pathology diagnoses were stratified into benign or malignant. Univariable and multivariable of regression analysis on variables potentially associated with PMB was performed.Results: A total of 381 patients were included, 91 in the vaccinated group and 290 in the unvaccinated group. Prevalence of PMB in the vaccinated group was 75.8% compared to 59.0% in the unvaccinated group (p < 0.005). No increase in endometrial malignant pathology was observed among the vaccinated group (p = 0.189). Multivariable analysis that correlates factors associated with PMB suggests COVID-19 vaccine and malignant endometrial biopsy as independent risk variables.Conclusions: A higher prevalence of PMB was associated with COVID-19 vaccine. Endometrial histological results showed no association with COVID-19 vaccination, but endometrial biopsy should be performed for PMB.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"489-493"},"PeriodicalIF":2.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141916225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The musculoskeletal syndrome of menopause. 更年期肌肉骨骼综合征。

IF 2.9 4区医学

Climacteric Pub Date : 2024-10-01 Epub Date: 2024-07-30 DOI: 10.1080/13697137.2024.2380363

Vonda J Wright, Jonathan D Schwartzman, Rafael Itinoche, Jocelyn Wittstein

{"title":"The musculoskeletal syndrome of menopause.","authors":"Vonda J Wright, Jonathan D Schwartzman, Rafael Itinoche, Jocelyn Wittstein","doi":"10.1080/13697137.2024.2380363","DOIUrl":"10.1080/13697137.2024.2380363","url":null,"abstract":"Fifty-one percent of humans are born with ovaries. As the ovarian production of estrogen diminishes in midlife and ultimately stops, it is estimated that more than 47 million women worldwide enter the menopause transition annually. More than 70% will experience musculoskeletal symptoms and 25% will be disabled by them through the transition from perimenopause to postmenopause. This often-unrecognized collective of musculoskeletal symptoms, largely influenced by estrogen flux, includes arthralgia, loss of muscle mass, loss of bone density and progression of osteoarthritis, among others. In isolation, it can be difficult for clinicians and patients to adequately appreciate the substantial role of decreasing estrogen, anticipate the onset of related symptoms and actively treat to mitigate future detrimental processes. Thus, in this review we introduce a new term, the musculoskeletal syndrome of menopause, to describe the collective musculoskeletal signs and symptoms associated with the loss of estrogen. Given the significant effects of these processes on quality of life and the associated personal and financial costs, it is important for clinicians and the women they care for to be aware of this terminology and the constellation of musculoskeletal processes for which proper risk assessment and prophylactic management are of consequence.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"466-472"},"PeriodicalIF":2.9,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141791999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper. 2024 年的更年期和 MHT：解决关键争议--国际更年期协会白皮书。

IF 2.8 4区医学

Climacteric Pub Date : 2024-09-13 DOI: 10.1080/13697137.2024.2394950

Nick Panay,Seng Bin Ang,Rebecca Cheshire,Steven R Goldstein,Pauline Maki,Rossella E Nappi,

{"title":"Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper.","authors":"Nick Panay,Seng Bin Ang,Rebecca Cheshire,Steven R Goldstein,Pauline Maki,Rossella E Nappi,","doi":"10.1080/13697137.2024.2394950","DOIUrl":"https://doi.org/10.1080/13697137.2024.2394950","url":null,"abstract":"The vision of the International Menopause Society (IMS) is that all women across the world will have easy and equitable access to evidence-based knowledge and health care, empowering them to make fully informed midlife health choices. The aim of this White Paper is to provide a well-balanced educational narrative of the menopause and menopause hormone therapy (MHT) from IMS experts, leading into World Menopause Day 2024. This is achieved by exploring the anthropology and history of menopause, the principles and controversies of prescribing MHT, and by placing this into regulatory and menopause society contexts. The White Paper also lays the groundwork for the forthcoming updated IMS recommendations on menopause and will act as a blueprint for the future ethical management of menopause from practical and aspirational perspectives. An important section of the paper is 'The 5Ws of prescribing MHT': WHO is MHT for; WHAT types and doses of MHT; WHEN should MHT be started and stopped; WHY is MHT important; WHERE can MHT be accessed? A key points summary of this information is provided for healthcare professionals and the public. The summary provides 'easy to access' advice regarding several recent controversial MHT prescribing issues in the healthcare and media spotlights.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":"35 1","pages":"1-17"},"PeriodicalIF":2.8,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142261074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Statement of Retraction: Role of topical oxytocin in improving vaginal atrophy in postmenopausal women: a randomized, controlled trial 撤回声明：局部催产素在改善绝经后妇女阴道萎缩方面的作用：随机对照试验

IF 2.8 4区医学

Climacteric Pub Date : 2024-09-10 DOI: 10.1080/13697137.2024.2399434

引用次数: 0

Willingness to use clinical scales for menopause management among general practitioners. 全科医生使用临床量表进行更年期管理的意愿。

IF 2.8 4区医学

Climacteric Pub Date : 2024-09-10 DOI: 10.1080/13697137.2024.2395986

Diana Farah,Pierre-François Ceccaldi,Line Farah,Jean-Marc Ayoubi,Alexandre Vallée

{"title":"Willingness to use clinical scales for menopause management among general practitioners.","authors":"Diana Farah,Pierre-François Ceccaldi,Line Farah,Jean-Marc Ayoubi,Alexandre Vallée","doi":"10.1080/13697137.2024.2395986","DOIUrl":"https://doi.org/10.1080/13697137.2024.2395986","url":null,"abstract":"OBJECTIVESThe use of digital healthcare technologies to enhance healthcare delivery has seen significant growth. However, a notable a notable research gap exists in the application of clinical scales for menopause management by general practitioners (GPs). This study aims to investigate willingness of GPs to use specific menopausal scale tools in the care of females for menopause management.METHODAn anonymous online survey was developed, which received responses from 348 French GPs in 2023. Multiple backward logistic regression was performed to identify the factors influencing the willingness to use a practical menopause management scale.RESULTSIn total, 87.93% of GPs are not familiar with the Greene Climacteric Scale and 90.52% are not familiar with the Menopause Quick 6 scale. In contrast, 90.52% would be interested in having access to such scales. The willingness to use a menopause management scale is associated with caring for menopausal females (odds ratio [OR] = 6.13, 95% confidence interval [CI] [2.08-18.08], p = 0.001), less experience (OR = 7.10, 95% CI [2.05-25.22], p = 0.002), the importance of health prevention in daily practice (comparing 'very important' to 'not', OR = 12.98, 95% CI [1.68-97.60], p = 0.004) and the use of a digital scale in daily practice for menopausal management (OR = 2.13, 95% CI [1.04-5.83], p = 0.014).CONCLUSIONFuture research is essential in representative population to confirm these findings in menopause management.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":"25 1","pages":"1-6"},"PeriodicalIF":2.8,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142192828","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial. 从红三叶中提取的异黄酮能同时改善更年期妇女的血脂异常和更年期症状：一项前瞻性随机安慰剂对照试验。

IF 2.8 4区医学

Climacteric Pub Date : 2024-09-10 DOI: 10.1080/13697137.2024.2393121

Ece Yigit,Saadet Unsal

{"title":"Isoflavones obtained from red clover improve both dyslipidemia and menopausal symptoms in menopausal women: a prospective randomized placebo-controlled trial.","authors":"Ece Yigit,Saadet Unsal","doi":"10.1080/13697137.2024.2393121","DOIUrl":"https://doi.org/10.1080/13697137.2024.2393121","url":null,"abstract":"OBJECTIVEThis study aimed to investigate the effects of red clover isoflavones on menopausal symptoms and the lipid profile in menopausal females.METHODSThis study included postmenopausal women with dyslipidemia. The red clover group (n = 39) received 40 mg isoflavone red clover capsule twice daily for 6 months, while placebo (n = 36) was 40 mg starch capsule twice daily. Data were collected at baseline, 3 months and 6 months. The Menopause Rating Scale (MRS) was applied to calculate subdimension and total scores.RESULTSThe two groups were similar in terms of age, MRS and lipid profile at baseline. In the red clover group, MRS scores decreased significantly at both 3 and 6 months. Similarly, total cholesterol, low-density lipoprotein cholesterol (LDL-C) and triglyceride levels decreased at both 3 months and 6 months. High-density lipoprotein cholesterol increased significantly from baseline to 3 months and 6 months. Except for LDL-C and MRS urogenital score at 3 months, the improvements were significantly in favor of red clover isoflavone treatment.CONCLUSIONSRed clover treatment for 3-6 months demonstrated significant improvements in lipid profiles and menopausal symptoms. While promising, further research is crucial to ascertain long-term safety and recommend the use of red clover isoflavones during menopause.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":"75 1","pages":"1-7"},"PeriodicalIF":2.8,"publicationDate":"2024-09-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142192830","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Management of obesity in menopause. 更年期肥胖管理。

IF 2.9 4区医学

Climacteric Pub Date : 2024-08-01 Epub Date: 2024-07-17 DOI: 10.1080/13697137.2024.2374760

Santiago Palacios, Peter Chedraui, Rafael Sanchez-Borrego, Pluvio Coronado, Tommaso Simoncini, Katrin Schauding, Tim Hillard, Rossella E Nappi

{"title":"Management of obesity in menopause.","authors":"Santiago Palacios, Peter Chedraui, Rafael Sanchez-Borrego, Pluvio Coronado, Tommaso Simoncini, Katrin Schauding, Tim Hillard, Rossella E Nappi","doi":"10.1080/13697137.2024.2374760","DOIUrl":"10.1080/13697137.2024.2374760","url":null,"abstract":"The increasing prevalence of obesity imposes significant health challenges, particularly in women undergoing menopause. Effective obesity management is essential to mitigate associated comorbidities and improve quality of life. The pillars of obesity treatment encompass lifestyle modifications, pharmacotherapy and surgical interventions. Pharmacotherapy may be considered for women who do not achieve adequate weight loss through lifestyle changes alone and have obesity or overweight with risk factors. Bariatric surgery is reserved for individuals with severe obesity or those with obesity-related complications. During menopause, hormonal changes contribute to weight gain and fat redistribution, complicating obesity management. Tailored treatment strategies are necessary to address the unique challenges faced by this population. The role of physicians and gynecologists is pivotal in the multidisciplinary approach to obesity management during menopause. Gynecologists are often the primary health-care providers for menopausal women and are in a unique position to offer guidance on weight management. They can provide personalized counseling, coordinate with nutritionists, endocrinologists and bariatric specialists, and monitor the effects of obesity and its treatment on reproductive health. By integrating obesity management into routine gynecological care, gynecologists can significantly impact the overall health and well-being of menopausal women.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"357-363"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141626155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan. 在日本进行的非索内酯治疗与更年期有关的血管运动症状的 II 期研究。

IF 2.9 4区医学

Climacteric Pub Date : 2024-08-01 Epub Date: 2024-06-12 DOI: 10.1080/13697137.2024.2356854

Kiyoshi Takamatsu, Takashi Miki, Kentaro Miyazaki, Atsuki Hashimoto, Weizhong He, Xuegong Wang

{"title":"Phase II study of fezolinetant for treatment of vasomotor symptoms associated with menopause in Japan.","authors":"Kiyoshi Takamatsu, Takashi Miki, Kentaro Miyazaki, Atsuki Hashimoto, Weizhong He, Xuegong Wang","doi":"10.1080/13697137.2024.2356854","DOIUrl":"10.1080/13697137.2024.2356854","url":null,"abstract":"Objective: The phase II STARLIGHT study was conducted to investigate the efficacy/safety of fezolinetant in Japanese women and identify the optimal dose for future evaluation.Method: Participants were perimenopausal/postmenopausal women aged ≥40 to ≤65 years from 36 centers in Japan seeking treatment/relief for vasomotor symptoms (VMS) associated with menopause. After screening, participants were randomized 1:1:1, stratified by menopausal status, to receive fezolinetant 15 or 30 mg or placebo orally once daily for 12 weeks. Participants completed a daily VMS diary. The primary endpoint was mean change in frequency of VMS of any severity from baseline to week 8. Secondary endpoints included mean change in VMS frequency from baseline each week up to week 12 and frequency/severity of adverse events.Results: A total of 147 participants were randomized (placebo, n = 47; fezolinetant 15 mg, n = 53; fezolinetant 30 mg, n = 47). Fezolinetant 15 and 30 mg demonstrated statistically significant reductions in mean VMS frequency at week 8 versus placebo. Least-squares mean estimates of mean change in frequency of VMS from baseline to week 8 were -7.04 for fezolinetant 15mg, -6.31 for fezolinetant 30mg, and -4.55 for placebo. The difference in least-squares mean estimates was -2.50 (95% CI: -4.03, -0.96), p = 0.002 for fezolinetant 15mg and placebo, and was -1.76 (95% confidence interval [CI]: -3.35, -0.17), p = 0.030 for fezolinetant 30mg and placebo. Reductions from baseline in mean VMS frequency versus placebo were seen after week 1 of treatment, maintained throughout 12 weeks. Fezolinetant was well tolerated, with no safety signals of concern for either dose to week 12.Conclusion: Oral fezolinetant at once-daily doses of 15 or 30 mg was efficacious and well tolerated for treatment of mild, moderate and severe VMS associated with menopause in this Japanese study.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"389-397"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141305557","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endocrine consequences of breast cancer therapy and survivorship. 乳腺癌治疗和幸存者的内分泌后果。

IF 2.9 4区医学

Climacteric Pub Date : 2024-08-01 Epub Date: 2024-06-12 DOI: 10.1080/13697137.2024.2354725

Meg Henze, Bronwyn G A Stuckey

{"title":"Endocrine consequences of breast cancer therapy and survivorship.","authors":"Meg Henze, Bronwyn G A Stuckey","doi":"10.1080/13697137.2024.2354725","DOIUrl":"10.1080/13697137.2024.2354725","url":null,"abstract":"Breast cancer survivorship is increasing, due to earlier diagnosis of the disease and more effective therapies. Long-term endocrine sequelae, including early menopause, bone health, fertility implications and menopausal symptoms, are important survivorship issues. Ovarian failure is common with chemotherapy and options for preserving fertility in young women include ovarian suppression during chemotherapy and oocyte or embryo cryopreservation before chemotherapy. Tamoxifen as adjunct therapy in premenopausal women leads to ovarian stimulation, sometimes ovulation and occasionally pregnancy with important teratogenic implications. Aromatase inhibitor therapy with or without gonadotrophin releasing hormone (GnRH) agonist leads to profound bone loss and anti-resorptive therapy is advised to prevent fracture. Tamoxifen acts to preserve bone in postmenopausal women but not premenopausal women. Pregnancy is not discouraged in young women with early breast cancer, even to the point of pausing adjunct therapy in order to conceive. However, menopausal hormone therapy is discouraged even years later. Non-hormonal therapy for menopausal symptoms in breast cancer survivors is available but, in some cases, estrogen-containing therapy may be worthy of consideration for quality of life in the informed patient.","PeriodicalId":10213,"journal":{"name":"Climacteric","volume":" ","pages":"333-339"},"PeriodicalIF":2.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141310203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fezolinetant for VMS: a balanced view on efficacy and safety needed - author's reply. 治疗 VMS 的非唑烷内酯：需要平衡疗效和安全性 - 作者回复。

IF 2.9 4区医学

Climacteric Pub Date : 2024-08-01 Epub Date: 2024-07-08 DOI: 10.1080/13697137.2024.2370864

Matheus Pedrotti Chavez, Eric Pasqualotto, Rafael Oliva Morgado Ferreira, Alexandre Hohl, Francisco Cezar Aquino de Moraes, Pedro Henrique Siedschlag Schmidt, Anna Luíza Soares de Oliveira Rodrigues, Joao Roberto de Sa

引用次数: 0